Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism,
represents a major cause of morbidity and mortality in patients with cancer. Arterial …

2.1. 1. Epidemiology and burden of the disease. The annual incidence of first episode of
symptomatic DVT in the adult population ranges from 50 to 100 per 100 000 population, with …

Background The optimal duration of anticoagulation in patients with active cancer and
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …

Background Ambulatory patients receiving systemic cancer therapy are at varying risk for
venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is …

This consensus document is proposed to clinicians to provide the whole spectrum of deep
vein thrombosis management as an update to the 2017 consensus document. New data …

BACKGROUND: The optimal duration of anticoagulation therapy for isolated distal deep
vein thrombosis in patients with cancer is clinically relevant, but the evidence is lacking. The …

Background The treatment of distal (below the knee) deep vein thrombosis (DVT) is not
clearly established. Distal DVT can either be treated with anticoagulation, or monitored with …

Background Data on recurrence after the end of anticoagulation for a first event of cancer-
associated venous thromboembolism (VTE) are scarce. Objectives Our aim was to assess …

PURPOSE Patients with isolated distal deep vein thrombosis (DVT) have lower rates of
adverse outcomes (death, venous thromboembolism [VTE] recurrence or major bleeding) …

Background Isolated distal deep vein thrombosis (IDDVT) is a common clinical presentation
of DVT. The efficacy and safety of anticoagulant therapy for the management of IDDVT in …